Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
Marinus Pharmaceuticals, Inc. (MRNS) plans to release its financial results for Q4 and FY 2020 on March 9, 2021, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the fourth quarter and fiscal year ended December 31, 2020 before the market opens on March 9, 2021. The company will host a conference call at 8:30am Eastern Time on March 9, 2021 to provide a business update and discuss the financial results.
Tuesday, March 9: 8:30 AM Eastern Time |
|||
Domestic: |
|
|
(833) 979-2765 |
International: |
|
|
(343) 761-2590 |
Webcast: |
|
|
https://event.on24.com/wcc/r/2948497/012AE4F51A475A8BDC3559C95635FBF2 |
Conference ID: |
|
2673136 |
|
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company is conducting a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005209/en/